Literature DB >> 25676738

Impact of antibiotic resistance on the development of recurrent and relapsing symptomatic urinary tract infection in kidney recipients.

M Bodro1, G Sanclemente, I Lipperheide, M Allali, F Marco, J Bosch, F Cofan, M J Ricart, N Esforzado, F Oppenheimer, A Moreno, C Cervera.   

Abstract

We sought to determine the frequency, risk factors, and clinical impact of recurrent urinary tract infections (UTI) in kidney transplant recipients. Of 867 patients who received a kidney transplant between 2003 and 2010, 174 (20%) presented at least one episode of UTI. Fifty-five patients presented a recurrent UTI (32%) and 78% of them could be also considered relapsing episodes. Recurrent UTI was caused by extended-spectrum betalactamase (ESBL)-producing Klebsiella pneumoniae (31%), followed by non-ESBL producing Escherichia coli (15%), multidrug-resistant (MDR) Pseudomonas aeruginosa (14%), and ESBL-producing E. coli (13%). The variables associated with a higher risk of recurrent UTI were a first or second episode of infection by MDR bacteria (OR 12; 95%CI 528), age >60 years (OR 2.2; 95%CI 1.15.1), and reoperation (OR 3; 95%CI 1.37.1). In addition, more relapses were recorded in patients with UTI caused by MDR organisms than in those with susceptible microorganisms. There were no differences in acute rejection, graft function, graft loss or 1 year mortality between groups. In conclusion, recurrent UTI is frequent among kidney recipients and associated with MDR organism. Classic risk factors for UTI (female gender and diabetes) are absent in kidney recipients, thus highlighting the relevance of uropathogens in this population. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  antibiotic drug resistance; bacterial; clinical research/practice; infection and infectious agents; infectious disease

Mesh:

Substances:

Year:  2015        PMID: 25676738     DOI: 10.1111/ajt.13075

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  19 in total

1.  Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: Results from a Spanish multicenter cohort.

Authors:  María Ruiz-Ruigómez; Mario Fernández-Ruiz; José Tiago Silva; Elisa Vidal; Julia Origüen; Antonia Calvo-Cano; Enrique Luna-Huerta; Esperanza Merino; Domingo Hernández; Cristina Jironda-Gallegos; Rosa Escudero-Sánchez; Francesca Gioia; Antonio Moreno; Cristina Roca; Elisa Cordero; Darío Janeiro; Beatriz Sánchez-Sobrino; María Milagro Montero; Dolores Redondo; Francisco Javier Candel; Isabel Pérez-Flores; Carlos Armiñanzas; Claudia González-Rico; María Carmen Fariñas; Emilio Rodrigo; Belén Loeches; María O López-Oliva; Miguel Montejo; Ricardo Lauzurica; Juan Pablo Horcajada; Julio Pascual; Amado Andrés; José María Aguado; Francisco López-Medrano
Journal:  Antimicrob Agents Chemother       Date:  2021-02-08       Impact factor: 5.191

2.  Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: A single center, retrospective study.

Authors:  Ian Hollyer; Francesca Varias; Bing Ho; Michael G Ison
Journal:  Transpl Infect Dis       Date:  2019-03-08       Impact factor: 2.228

3.  Risk Factors and Outcomes of Acute Graft Pyelonephritis with Bacteremia Due to Multidrug-Resistant Gram-Negative Bacilli among Kidney Transplant Recipients.

Authors:  Núria Sabé; Marta Maristany; Manel Tuells; Alexandre Favà; Edoardo Melilli; Fe Tubau; Josep Maria Cruzado; Jordi Carratalà
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

4.  Modelling of the transmission dynamics of carbapenem-resistant Klebsiella pneumoniae in hospitals and design of control strategies.

Authors:  Suttikiat Changruenngam; Charin Modchang; Dominique J Bicout
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.996

5.  Antibiotic Prophylaxis Is Associated with Subsequent Resistant Infections in Children with an Initial Extended-Spectrum-Cephalosporin-Resistant Enterobacteriaceae Infection.

Authors:  Sibani Das; Amanda L Adler; Arianna Miles-Jay; Matthew P Kronman; Xuan Qin; Scott J Weissman; C A Burnham; Alexis Elward; Jason G Newland; Rangaraj Selvarangan; Kaede V Sullivan; Theoklis Zaoutis; Danielle M Zerr
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.

Authors:  Eliana S Armstrong; Janelle A Mikulca; Daniel J Cloutier; Caleb A Bliss; Judith N Steenbergen
Journal:  BMC Infect Dis       Date:  2016-11-25       Impact factor: 3.090

7.  Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen.

Authors:  Gianluigi Zaza; Alessandra Dalla Gassa; Giovanna Felis; Simona Granata; Sandra Torriani; Antonio Lupo
Journal:  PLoS One       Date:  2017-05-24       Impact factor: 3.240

8.  Increased resistance of gram-negative urinary pathogens after kidney transplantation.

Authors:  Johannes Korth; Julia Kukalla; Peter-Michael Rath; Sebastian Dolff; Marco Krull; Hana Guberina; Anja Bienholz; Benjamin Wilde; Stefan Becker; Birgit Ross; Olympia Evdoxia Anastasiou; Andreas Kribben; Oliver Witzke
Journal:  BMC Nephrol       Date:  2017-05-19       Impact factor: 2.388

Review 9.  Asymptomatic Bacteriuria in Post Renal Transplant Patients: To Treat or Not?

Authors:  Anas O Almaimani
Journal:  Cureus       Date:  2021-06-17

10.  Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.

Authors:  Maria José Espinar; Isabel M Miranda; Sofia Costa-de-Oliveira; Rita Rocha; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  PLoS One       Date:  2015-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.